Group 1 - Roche (RHHBY.US) announced that patients with obesity receiving its experimental weight loss drug CT-388 lost 18% more weight compared to those receiving a placebo in a mid-stage trial [1] - CT-388 is a GLP-1R/GIPR agonist developed by Carmot Therapeutics, which Roche plans to acquire for $3.1 billion, marking its return to the GLP-1 market [1] - Roche previously developed a GLP-1 receptor agonist, Taspoglutide, which was abandoned in 2011 due to side effects [1] Group 2 - CT-388 is a weekly subcutaneous injection designed for treating obesity and type 2 diabetes (T2D), showing a maximum weight reduction of 18.3% after 48 weeks in treated subjects [2] - The safety profile of CT-388 is favorable, with most gastrointestinal adverse events being mild to moderate, and a low treatment discontinuation rate due to adverse events (5.9% for CT-388 vs. 1.3% for placebo) [2] - Roche plans to initiate late-stage trials this quarter, testing CT-388 both as a standalone therapy and in combination with other weight loss treatments [2] Group 3 - Analyst Stefan Schneider from Vontobel expects Roche to launch CT-388 by 2028, with peak sales estimated to reach 2.5 billion Swiss francs [2]